Covid-19 Respiratory Sequelae French Cohort (PNEUMOCOVID)

NCT05075785 COMPLETED

As the investigators need data on long term outcome of Covid-19, especially respiratory sequelae, a national cohort is required. To better evaluate the potential respiratory sequelae after SARS-CoV-2 infection, it is fundamental to include patients with different management at the acute phase of the Covid-19: ambulatory management, hospitalization in non ICU and in ICU units. That is why the investigators will conduct a national cohort study with all components of french pneumology which will give the investigators the opportunity to include patients in general hospital, in university hospital and in private structure. As it is a "real life" study, the investigators will include all patients who will have a consultation with a pneumologist for an evaluation 5 to 7 months after a Covid-19 infection whatever their acute disease management. The investigators will collect all available data on Covid-19 acute phase, on patients characteristics and comorbidities, on persistent symptoms after Covid-19, on exams results during the outcome evaluation (CT-scan, 6 min walk test, spirometry and DLCO, blood gas, VO2 max if realized).

Details

Lead sponsor	Centre Hospitalier Universitaire, Amiens
Status	COMPLETED
Enrolment	2933
Start date	Thu Oct 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed May 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• COVID-19
• Fibrosis
• Cohort
• Follow-up
• Sequelae
• Spirometry DLCO

Countries

France